Nyxoah S.A. (NYXH)
9.32
0.12 (1.30%)
At close: Jan 14, 2025, 3:57 PM
9.32
0.00%
After-hours Jan 14, 2025, 03:58 PM EST
undefined% (undefined)
| Bid | 8.89 |
| Market Cap | 320.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -5.24 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.89 |
| Volume | 109,579 |
| Avg. Volume (20D) | 37,288 |
| Open | 9.35 |
| Previous Close | 9.20 |
| Day's Range | 9.07 - 9.57 |
| 52-Week Range | 4.00 - 20.00 |
| Beta | undefined |
About NYXH
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium....
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Apr 28, 2021
Employees 146
Stock Exchange NASDAQ
Ticker Symbol NYXH
Website https://www.nyxoah.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NYXH stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 82.40% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Nyxoah S.A. is scheduled to release its earnings on Mar 13, 2025,
during market hours.
Analysts project revenue of $2.67M, reflecting a 36.02% YoY growth and earnings per share of -0.47, making a 15.20% increase YoY.
Analysts project revenue of $2.67M, reflecting a 36.02% YoY growth and earnings per share of -0.47, making a 15.20% increase YoY.
1 month ago ·
Source
+1.52%
Nyxoah shares are trading higher after the company...
Unlock content with
Pro Subscription
7 months ago ·
Source
-17.69%
Nyxoah shares are trading lower after the company announced the pricing of a $50 million public offering of 5,374,755 shares at $9.25 per share.
